“We are looking forward to this partnership with MD Anderson and believe the collaboration will result in COTI-2 one day becoming a breakthrough therapy not only for ovarian cancer patients, but for many patients with other common cancers. MD Anderson ranks as one of the world’s most respected cancer centers focused on patient care, research, education, and prevention. It has the state-of-the-art facilities, technical capabilities and expertise to successfully execute the clinical development of COTI-2. Dr. Mills and his team have been conducting experiments with COTI-2 for the past 21 months and are very familiar with its mechanism of action. We believe they are in the best position to partner with us as we move the compound forward into clinical trials.” - Dr. Wayne Danter, President and CEO of Critical Outcome Technologies Inc.
Critical Outcome and MD Anderson Cancer Center Sign Letter of Intent for Phase 1 Development of COTI-2
This morning we announced that we had signed a letter of intent (“LOI”) with The University of Texas MD Anderson Cancer Center in Houston (“MD Anderson”), for the Phase 1 clinical development of our lead cancer drug candidate, COTI-2, in gynecological cancers.
Under the terms of the proposed agreement, both parties will work together to design and conduct a first in humans (Phase 1) study with oral COTI-2 in up to 40 women with advanced gynecological (ovary, endometrium, and cervix) cancers who have failed conventional therapy. The parties anticipate that patient recruitment for the Phase 1 clinical trial will begin in early 2015. The co-principal investigators for the COTI-2 Phase 1 clinical trial will be Dr. Gordon B. Mills and Dr. Shannon Westin MD from MD Anderson.
Related to this post:
Welcome to our blog. We use this space to provide more insight into the latest developments in our business as well as recent events in the field of drug discovery and development.